SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:liu-116513"
 

Search: id:"swepub:oai:DiVA.org:liu-116513" > Reductions in serum...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Angelin, BoKarolinska Institutet (author)

Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome

  • Article/chapterEnglish2015

Publisher, publication year, extent ...

  • 2014-05-16
  • Wiley: 12 months,2015
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-116513
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-116513URI
  • https://doi.org/10.1111/joim.12261DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:130775326URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies|Karo Bio
  • BackgroundLiver-selective thyromimetic agents could provide a new approach for treating dyslipidaemia. MethodsWe performed a multicentre, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of eprotirome, a liver-selective thyroid hormone receptor agonist, in 98 patients with primary hypercholesterolaemia. After previous drug wash-out and dietary run-in, patients received 100 or 200gday(-1) eprotirome or placebo for 12weeks. The primary end-point was change in serum LDL cholesterol; secondary end-points included changes in other lipid parameters and safety measures. ResultsEprotirome treatment at 100 and 200g daily reduced serum LDL cholesterol levels by 235% and 31 +/- 4%, respectively, compared with 2 +/- 6% for placebo (Pless than0.0001). Similar reductions were seen in non-HDL cholesterol and apolipoprotein (apo) B, whereas serum levels of HDL cholesterol and apo A-I were unchanged. There were also considerable reductions in serum triglycerides and lipoprotein(a), in particular in patients with elevated levels at baseline. There was no evidence of adverse effects on heart or bone and no changes in serum thyrotropin or triiodothyronine, although the thyroxine level decreased. Low-grade increases in liver enzymes were evident in most patients. ConclusionIn hypercholesterolaemic patients, the liver-selective thyromimetic eprotirome decreased serum levels of atherogenic lipoproteins without signs of extra-hepatic side effects. Selective stimulation of hepatic thyroid hormone receptors may be an attractive way to modulate lipid metabolism in hyperlipidaemia.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Kristensen, Jens D.Karo Bio AB, Sweden (author)
  • Eriksson, MatsKarolinska Institutet (author)
  • Carlsson, BoKaro Bio AB, Sweden (author)
  • Klein, IrwinNYU, NY USA (author)
  • Olsson, AndersLinköpings universitet,Avdelningen för kardiovaskulär medicin,Hälsouniversitetet,Region Östergötland, Endokrinmedicinska kliniken,Stockholm Heart Centre, Sweden(Swepub:liu)andol21 (author)
  • Chester Ridgway, E.University of Colorado, CO USA (author)
  • Ladenson, Paul W.Johns Hopkins University, MD 21205 USA (author)
  • Karolinska InstitutetKaro Bio AB, Sweden (creator_code:org_t)

Related titles

  • In:Journal of Internal Medicine: Wiley: 12 months277:3, s. 331-3420954-68201365-2796

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view